Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/3/2016 |
| Start Date: | April 2006 |
| End Date: | October 2009 |
A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
To determine the safety of Alimta when used with chemoradiation in inoperable non small cell
lung cancer
lung cancer
To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when
administered concurrently with carboplatin and thoracic radiation therapy.
To determine, qualitatively, the occurrence of local tumor responses identified with this
regimen.
administered concurrently with carboplatin and thoracic radiation therapy.
To determine, qualitatively, the occurrence of local tumor responses identified with this
regimen.
Inclusion Criteria:
- Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on
planning CT scan Zubrod 0-1 Weight loss equal to or less than 10% 3 months prior to
diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions
Exclusion Criteria:
- Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or
lower neck radiatio therapy
We found this trial at
1
site
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
Click here to add this to my saved trials
